Press Release

NATCO

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Hyderabad, India, May 29th, 2026: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today announced results for fourth quarter and financial year 2026.

NATCO records ₹816.9 Crore consolidated revenue and ₹269.0 Crore of profit after tax for Q4 FY26 and 4,375.9 Crore of revenue & 1,418.5 Crore profit after tax for FY26

NATCO recorded consolidated total revenue of INR 4,375.9 Crore for the year ended on 31st March 2026, as against INR 4,784.0 Crore for the last year. The net profit for the period, on a consolidated basis, was INR 1,418.5 Crore, as against INR 1,883.4 Crore last year.

For the fourth quarter (Q4) ended March 31st, 2026, the Company recorded a net revenue of INR 816.9 Crore, on a consolidated basis, as against INR 1,287.3 Crore during Q4, FY 2025. The profit for the fourth quarter, on a consolidated basis, was INR 269.0 Crore including share of profit of associate, as against INR 406.0 Crore same period last year.

Net profit for the quarter and financial year includes one-time benefit of INR 115 Crore as the Company has elected to move to the new tax regime from FY26-27 and has re-measured its deferred tax assets on MAT credit and other deferred tax assets/liabilities.

For the quarter, revenue from the associate Company Adcock Ingram Holdings Limited, South Africa was at INR 1,208.2 Crore and profit after tax was at INR 102.5 Crore. NATCO's share of profit based on the current holding stood at INR 35.7 Crore.

Segmental Revenue Split (INR Crore)

Business Segments	Q4FY26	FY26
Active Pharmaceutical Ingredients (API)	63.9	234.7
Domestic Formulations	108.7	440.9
Formulations export (Incl. profit share and subs)	539.6	3,234.5
Crop Health Sciences (CHS)	22.6	138.2
Other operating and non-operating income	82.1	327.5
Total	**816.9**	**4,375.9**

NATCO Pharma Ltd

NATCO House
Road No.2, Banjara Hills
Hyderabad-500 034, India

About NATCO Pharma Limited

NATCO Pharma Limited (www.natcopharma.com), (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharma ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com or click on LinkedIn or X (formerly Twitter).

Earnings Call Details:

- *Date: 29th May 2026, Friday*
- *Time: 4.30 PM IST*
- ***Dial-in-Numbers:***
    - *India: (+91 22) 62801222 / 71158123*
    - *US: 18667462133*
    - *UK: 08081011573*
    - *Singapore: 8001012045*

For further information please contact:

Rajeev Menon, Investor Relations

ir@natcopharma.co.in/r.menon@natcopharma.co.in